BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, July 4, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for April 6, 2022

April 6, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amniotics, BMS, CNS, Starton, Tiziana.
Read More

Other news to note for April 6, 2022

April 6, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3CL, Abbvie, Addex, Agenus, Aligos, Alloy, Alvotech, Atara, Atreca, AVM, Awakn, Axantia, Betterlife, Biotech Acquisition, Cellpoint, Dragon Overseas, Golden Mountain, HDT, Intas, Isto, Stada, Neurona, Novartis, Neuro-Bio, Novo Nordisk, Oncotelic, Oragenics, Pregene, Regeneron, SQZ, Synaptogenix, Swanbio, Tegmine, Theracell, Todos, Treadwell, Vigeneron, Zymeworks.
Read More

In the clinic for April 6, 2022

April 6, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, Aldeyra, Allergan, Amylyx, Argenx, Artios, Attralus, Bayer, Beckley, Bond, Corcept, Cymabay, Imara, Lakewood-Amedex, Newamsterdam, Novartis, Nurix, Realta, Respira, Theravance, VBI, Verrica.
Read More
Red blood cells and coronavirus

ACE2-independent blood cell infection linked to severe COVID

April 6, 2022
By Anette Breindl
Investigators at Boston Children's Hospital have demonstrated that SARS-CoV-2 infection of blood monocytes and lung macrophages in the lung could kill the cells via pyroptosis, increasing inflammation and leading to severe COVID-19.
Read More
U.S. health compass

Senators: Time to plan for the beginning of the end of US health emergency

April 5, 2022
By Mari Serebrov
Even as many in the U.S. are looking for the end of the COVID-19 public health emergency, Health and Human Services (HHS) Secretary Xavier Becerra reinforced expectations April 5 that he will continue the emergency declaration into the summer, if not beyond. When asked during a Senate Finance Committee budget hearing if he saw the emergency ending this summer, Becerra declined to give a date, but reiterated his commitment to give stakeholders at least 60 days’ notice.
Read More
mRNA on digital background

Sunshine Biopharma continues its move into mRNA cancer treatment

April 5, 2022
By Lee Landenberger
Preclinical data on two newly designed mRNA molecules from Sunshine Biopharma Inc., of Montreal, showed they are effective at killing cancer cells grown in culture. Tests were performed on a variety of cancer cells, including multidrug-resistant breast cancer cells, ovarian adenocarcinoma cells and pancreatic cancer cells, while toxicology studies using normal human cells showed that the mRNA molecules had little or no cytotoxic effects.
Read More

Regulatory actions for April 5, 2022

April 5, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Accutar, Acer, Alnylam, Ascletis, Blade, Cansino, Curis, Immunitybio, Immunocore, Janssen, Junshi, JW, Kite, Nobelpharma, Precigen, Regeneron, Roche, Sanofi.
Read More

Other news to note for April 5, 2022

April 5, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Celeristx, Boehringer, Ginkgo, Iktos, Microba, Teijin, Tonix.
Read More
Earth threatened by virus

U.S. infections subside, globe struggles, as development candidates hit 1,058

April 4, 2022
By Karen Carey
After COVID-19 reached a pandemic peak in January due to the omicron variant, infections in the U.S. are now hitting the lowest levels since March of 2020. During the past week, there were 195,963 confirmed SARS-CoV-2 infections in the country, according to Johns Hopkins University data. That is 5.5% fewer infections than the same week two years ago and 56% fewer than last year. Deaths are also down to 5,602 for the week, although there were lower points in the spring and summer months of 2020 and 2021.
Read More

Other news to note for April 4, 2022

April 4, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aligos, Alpine, Aqualung, Copernicus, G1, Gridiron, Inmune, Innovation1, Northeastern University, ST.
Read More
Previous 1 2 … 119 120 121 122 123 124 125 126 127 … 553 554 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Illustration demonstrating gut-brain axis

    CINP 2026: Gut microbiota could predict antidepressant response

    BioWorld
    The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
  • Black wavy lines forming an abstract sound wave.png

    Deep brain stimulation from the shallows: tomorrow’s BCI technology?

    BioWorld
    Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
  • Brain made of chip and circuits

    Ascending BCI systems deepen national security, ethical concerns

    BioWorld
    Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing